EMA OST-HER2 coverage for business development, investment, and market access teams
OST-HER2 is set for a 2026 EMA review following promising survival data, presenting significant implications for investors and pharma teams.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
